Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686

Diabetes Care. 2016 Jan;39(1):e19. doi: 10.2337/dci15-0026.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Canagliflozin / adverse effects*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetic Ketoacidosis / chemically induced*
  • Female
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Male

Substances

  • Hypoglycemic Agents
  • Canagliflozin